InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,732.65
(
-0.10%
)
Post# of 251790
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: seschm post# 213680

Monday, 09/18/2017 2:18:06 PM

Monday, September 18, 2017 2:18:06 PM

Post# of 251790
(ABBV/ENTA)—Leerink on GILD:

http://www.barrons.com/articles/gilead-sciences-is-the-kite-deal-too-little-too-late-1505748947

We forecast that total HCV revenue at Gilead will decline by 30% in 2017, and then by 15-25%/year through 2020. This decline is likely to accelerate in 2017E and beyond as better competitive HCV regimens come to market.

The word, regimens above should be regimen (singular) because there’s only one competing product that pertains: ABBV/ENTA’s Mavyret.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up